# US 2021/0268092 A1 · Subunit vaccine delivery platform for robust humoral and cellular immune responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0268092 A1
- Document ID: US20210268092A1
- Status: Published application
- Kind: A1
- Application number: 17/139,280
- Filed: 2020-12-31
- Published: 2021-09-02
- Earliest claimed: 2012-04-06
- Assignees: Cornell University
- Applicants: Cornell University
- Inventors: David A. Putnam; Joseph Rosenthal; Chung-Jr Huang; Matthew DeLisa; Susana Mendez
- Web page: https://patentgrep.com/patent/US20210268092A1

## CPC

- A61K 39/015: Hemosporidia antigens, e.g. Plasmodium antigens
- A61K 38/164: {from bacteria}
- A61K 39/04: Mycobacterium, e.g. Mycobacterium tuberculosis
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61K 39/35: Allergens
- A61K 39/38: Antigens from snakes
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- A61K 2039/52: {Bacterial cells; Fungal cells; Protozoal cells}
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/6068: {Other bacterial proteins, e.g. OMP}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.

## Claims

### Claim 1

A probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides.

### Claim 2 (depends on 1)

The probiotic cell of claim 1, wherein the probiotic cell is mutated to hyperexpress vesicles containing the fusion protein.

### Claim 3 (depends on 1)

The probiotic cell of claim 1, wherein the transport protein is an adhesin, immunomodulatory compound, protease, or toxin.

### Claim 4 (depends on 1)

The probiotic cell of claim 1, wherein the transport protein is ClyA.

### Claim 5 (depends on 1)

The probiotic cell of claim 1, wherein the antigenic protein or peptide is derived from pathogenic bacterial, fungal or viral organisms, Streptococcus species, Candida species, Brucella species, Salmonella species, Shigella species, Pseudomonas species, Bordetella species, Clostridium species, Norwalk virus, Bacillus anthracis, Mycobacterium tuberculosis, human immunodeficiency virus (HIV), Chlamydia species, Human Papillomaviruses, Influenza virus, Paramyxovirus species, Herpes virus, Cytomegalovirus, Varicella-Zoster virus, Epstein-Barr virus, Hepatitis viruses, Plasmodium species, Trichomonas species, sexually transmitted disease agents, viral encephalitis agents, protozoan disease agents, fungal disease agents, bacterial disease agents, cancer cells, or combinations.

### Claim 6 (depends on 1)

The probiotic cell of claim 1, wherein the probiotic cell is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim 7

(canceled)

### Claim 8 (depends on 7)

The probiotic cell of claim 7, wherein the fusion protein comprises at least a portion of a ClyA protein coupled to at least a portion of one or more antigenic proteins or peptides.

### Claim at position 9

9-15. (canceled)

### Claim 16

A probiotic-derived vesicle displaying a fusion protein, wherein said fusion protein comprises at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides.

### Claim 17 (depends on 16)

The probiotic-derived vesicle of claim 16, wherein the transport protein is an adhesin, immunomodulatory compound, protease, or toxin.

### Claim 18 (depends on 17)

The probiotic-derived vesicle of claim 17, wherein the transport protein is ClyA.

### Claim 19 (depends on 16)

The probiotic-derived vesicle cell of claim 16, wherein the antigenic protein or peptide is derived from pathogenic bacterial, fungal or viral organisms, Streptococcus species, Candida species, Brucella species, Salmonella species, Shigella species, Pseudomonas species, Bordetella species, Clostridium species, Norwalk virus, Bacillus anthracis, Mycobacterium tuberculosis, human immunodeficiency virus (HIV), Chlamydia species, Human Papillomaviruses, Influenza virus, Paramyxovirus species, Herpes virus, Cytomegalovirus, Varicella-Zoster virus, Epstein-Barr virus, Hepatitis viruses, Plasmodium species, Trichomonas species, sexually transmitted disease agents, viral encephalitis agents, protozoan disease agents, fungal disease agents, bacterial disease agents, cancer cells, or combinations.

### Claim 20 (depends on 16)

The probiotic-derived vesicle of claim 16, wherein the probiotic-derived vesicle is from a cell selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The probiotic-derived vesicle of claim 20, wherein the vesicle displays a fusion protein comprising at least a portion of a ClyA protein coupled to at least a portion of one or more antigenic proteins or peptides.

### Claim at position 17

23-28. (canceled)

### Claim 29

A probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic food allergy proteins or peptides.

### Claim 30 (depends on 29)

The probiotic cell of claim 29, wherein the probiotic cell is mutated to hyperexpress vesicles containing the fusion protein.

### Claim 31 (depends on 29)

The probiotic cell of claim 29, wherein the transport protein is an adhesin, immunomodulatory compound, protease, or toxin.

### Claim 32 (depends on 29)

The probiotic cell of claim 29, wherein the transport protein is ClyA.

### Claim 33 (depends on 29)

The probiotic cell of claim 29, wherein the antigenic food allergy proteins or peptides are derived from milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, coconut, and soybeans.

### Claim 34 (depends on 33)

The probiotic cell of claim 33, wherein the food allergy is against peanuts and the antigenic protein or peptide is Arah2.

### Claim 35 (depends on 29)

The probiotic cell of claim 29, wherein the probiotic cell is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim 36

(canceled)

### Claim 37

A probiotic-derived vesicle displaying a fusion protein, wherein said fusion protein comprises at least a portion of a transport protein coupled to at least a portion of one or more antigenic food allergy proteins or peptides.

### Claim 38 (depends on 37)

The probiotic-derived vesicle of claim 37, wherein the transport protein is an adhesin, immunomodulatory compound, protease, or toxin.

### Claim 39 (depends on 37)

The probiotic-derived vesicle of claim 37, wherein the transport protein is ClyA.

### Claim 40 (depends on 37)

The probiotic-derived vesicle of claim 37, wherein the antigenic food allergy proteins or peptides are derived from milk, eggs, fish, crustacean shellfish, tree nuts, peanuts, wheat, coconut, and soybeans.

### Claim 41 (depends on 40)

The probiotic-derived vesicle of claim 40, wherein the food allergy is against peanuts and the antigenic food allergy protein or peptide is Arha2.

### Claim 42 (depends on 37)

The probiotic-derived vesicle of claim 37, wherein the probiotic-derived vesicle is from a cell selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim at position 32

43-53. (canceled)

### Claim 54 (depends on 1)

The probiotic cell of claim 1, wherein the antigenic viral protein or peptide is from Human Immunodeficiency Virus (HIV), influenza A virus, influenza B virus, influenza C virus, rabies virus, vesicular stomatitis virus, respiratory syncytial virus, measles virus, parainfluenza virus, mumps virus, yellow fever virus, west nile virus, dengue virus, rubella virus, sindbis virus, semliki forest virus, ross river virus, rotavirus, parvovirus, JC polyoma virus, BK polyoma virus, Human papillomavirus (HPV), adenovirus, hepatitis B virus, hepatitis C virus, hepatitis A virus, hepatitis E virus, Human herpesvirus, vaccinia virus, monkeypox virus, cowpox virus, human T-cell leukemia virus, coxsackie virus, polio virus, rhinovirus, enterovirus, echovirus, ebola virus, coronavirus, variola virus, hantaan virus, adeno-associated virus, astrovirus, hendra virus, lassa virus, nipah virus, Marburg virus, or Norwalk virus.

### Claim 55 (depends on 54)

The probiotic cell of claim 54, wherein the virus is influenza or coronavirus.

### Claim 56 (depends on 1)

The probiotic cell of claim 1, wherein the probiotic cell is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim 57 (depends on 56)

The probiotic cell of claim 56, wherein the probiotic cell is Escherichia coli Nissle.

### Claim at position 37

58-70. (canceled)

### Claim 71

A probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic intracellular bacterial proteins or peptides.

### Claim 72 (depends on 71)

The probiotic cell of claim 71, wherein the probiotic cell is mutated to hyperexpress vesicles containing the fusion protein.

### Claim 73 (depends on 71)

The probiotic cell of claim 71, wherein the transport protein is an adhesin, immunomodulatory compound, protease, or toxin.

### Claim 74 (depends on 71)

The probiotic cell of claim 71, wherein the transport protein is ClyA.

### Claim 75 (depends on 71)

The probiotic cell of claim 71, wherein the antigenic intracellular bacterial protein or peptide is from Chlamydophila, Ehrlichia, Rickettsia, Mycobacterium, Brucella, Francisella, Legionella, or Listeria.

### Claim 76 (depends on 75)

The probiotic cell of claim 75, wherein the bacteria is from Mycobacterium paratuberculosis and the antigenic intracellular bacterial protein or peptide is 74F protein.

### Claim 77 (depends on 71)

The probiotic cell of claim 71, wherein the probiotic cell is selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim 78

(canceled)

### Claim 79

A probiotic-derived vesicle displaying a fusion protein, wherein said fusion protein comprises at least a portion of a transport protein coupled to at least a portion of one or more antigenic intracellular bacterial proteins or peptides.

### Claim 80 (depends on 79)

The probiotic-derived vesicle of claim 79, wherein the transport protein is an adhesin, immunomodulatory compound, protease, or toxin.

### Claim 81 (depends on 79)

The probiotic-derived vesicle of claim 79, wherein the transport protein is ClyA.

### Claim 82 (depends on 79)

The probiotic-derived vesicle of claim 79, wherein the antigenic intracellular bacterial protein or peptide is from Chlamydophila, Ehrlichia, Rickettsia, Mycobacterium, Brucella, Francisella, Legionella, or Listeria.

### Claim 83 (depends on 82)

The probiotic-derived vesicle of claim 82, wherein the bacteria is from Mycobacterium paratuberculosis and the antigenic intracellular bacterial protein is 74F protein.

### Claim 84 (depends on 79)

The probiotic-derived vesicle of claim 79, wherein the probiotic-derived vesicle is from a cell selected from the group consisting of Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium adolescentis, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus salivarius, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus johnsonii, Lactobacillus plantarum, Lactobacillus fermentum, Lactococcus lactis, Streptococcus thermophilus, Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, Lactobacillus bulgaricus, Lactobacillus helveticus, Lactobacillus delbrueckii, Escherichia coli, and mixtures thereof.

### Claim 85 (depends on 84)

The probiotic-derived vesicle of claim 84, wherein the probiotic-derived vesicle is from Escherichia coli Nissle.

### Claim 86 (depends on 71)

A method of immunizing an animal against an intracellular bacterial infection, said method comprising:
selecting an animal at risk of developing an intracellular bacterial infection;
providing the probiotic cell of claim 71; and
administering the probiotic cell to the selected animal under conditions effective to immunize the animal against the intracellular bacterial infection.

### Claim at position 54

87-93. (canceled)
